Evidence map›Paper›PMID 26726832›Full record

ArticleScientific reports2016

Fortilin potentiates the peroxidase activity of Peroxiredoxin-1 and protects against alcohol-induced liver damage in mice.

Abhijnan Chattopadhyay, Decha Pinkaew, Hung Q Doan, Reed B Jacob, Sunil K Verma, Hana Friedman, Alan C Peterson, Muge N Kuyumcu-Martinez, Owen M McDougal, Ken Fujise

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Tick HRF-dependent ferroptosis pathway to promote tick acquisition ofFrontiers in cellular and infection microbiology · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Abhijnan ChattopadhyayDivision of Cardiology, Department of Internal Medicine, University of Texas Medical Branch at Galveston, TX 77555, USA.
Decha PinkaewDivision of Cardiology, Department of Internal Medicine, University of Texas Medical Branch at Galveston, TX 77555, USA.
Hung Q DoanDivision of Cardiology, Department of Internal Medicine, University of Texas Medical Branch at Galveston, TX 77555, USA.
Reed B JacobDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA.
Sunil K VermaDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch at Galveston, TX 77555, USA.
Hana FriedmanMcGill University, Montreal, Quebec, Canada.
Alan C PetersonMcGill University, Montreal, Quebec, Canada.
Muge N Kuyumcu-MartinezDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch at Galveston, TX 77555, USA.
Owen M McDougalDepartment of Chemistry and Biochemistry, Boise State University, 1910 University Drive, Boise, ID 83725-1520, USA.
Ken FujiseDivision of Cardiology, Department of Internal Medicine, University of Texas Medical Branch at Galveston, TX 77555, USA.
The University of Texas Medical Branch at Galveston · USMcGill University · CABoise State University · USUniversity of North Carolina at Chapel Hill · US

Funding

Fortilin, p53, and atherosclerosisR01HL117247 · NHLBI · UNIVERSITY OF WASHINGTON · PI CHEN, SHIYOU, FUJISE, KEN · 2013 to 2023
$4.7M
Novel mechanism of smooth muscle phenotypic modulation and vascular remodelingR01HL119053 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CHEN, SHIYOU · 2014 to 2023
$3.8M
Characterization of Fortilin, A Novel Anti-p53 ProteinR01HL068024 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FUJISE, KEN · 2001 to 2005
$992k
CIHRNHLBI NIH HHS HL117247NHLBI NIH HHS HL68024NHLBI NIH HHS R01 HL068024NHLBI NIH HHS R01 HL117247NHLBI NIH HHS R01 HL119053
6 · The paper itself

Abstract

Fortilin, a pro-survival molecule, inhibits p53-induced apoptosis by binding to the sequence-specific DNA-binding domain of the tumor suppressor protein and preventing it from transcriptionally activating Bax. Intriguingly, fortilin protects cells against ROS-induced cell death, independent of p53. The signaling pathway through which fortilin protects cells against ROS-induced cell death, however, is unknown. Here we report that fortilin physically interacts with the antioxidant enzyme peroxiredoxin-1 (PRX1), protects it from proteasome-mediated degradation, and keeps it enzymatically active by blocking its deactivating phosphorylation by Mst1, a serine/threonine kinase. At the whole animal level, the liver-specific overexpression of fortilin reduced PRX1 phosphorylation in the liver, enhanced PRX1 activity, and protected the transgenic animals against alcohol-induced, ROS-mediated, liver damage. These data suggest the presence of a novel oxidative-stress-handling pathway where the anti-p53 molecule fortilin augments the peroxidase PRX1 by protecting it against degradation and inactivation of the enzyme. Fortilin-PRX1 interaction in the liver could be clinically exploited further to prevent acute alcohol-induced liver damage in humans.

Indexed as

AlcoholsAnimalsApoptosisBiomarkers, TumorDisease Models, AnimalEnzyme ActivationGene ExpressionHepatocyte Growth FactorHomeodomain ProteinsLiver DiseasesMiceOxidation-ReductionPeroxiredoxinsPhosphorylationProteasome Endopeptidase ComplexProtein BindingAlcoholsBiomarkers, TumorHepatocyte Growth FactorHomeodomain Proteinsmacrophage stimulating proteinPeroxiredoxinsProteasome Endopeptidase ComplexProto-Oncogene ProteinsPrrx1 protein, mouseReactive Oxygen SpeciesTumor Protein, Translationally-Controlled 1Tumor Suppressor Protein p53

Identifiers

PMID26726832
PMCPMC4698670
OpenAlexW2228157758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.